Trials / Completed
CompletedNCT03725852
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter, exploratory Phase 2 study including participants with Idiopathic Pulmonary Fibrosis (IPF), investigating GLPG1205 in addition to the local standard of care (defined as receiving nintedanib, pirfenidone, or neither nintedanib nor pirfenidone).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG1205 | GLPG1205 will be provided as an oral hard gelatin capsule. |
| DRUG | Placebo | GLPG1205 matching placebo will be provided as an oral hard gelatin capsule. |
Timeline
- Start date
- 2018-09-27
- Primary completion
- 2020-07-21
- Completion
- 2020-08-14
- First posted
- 2018-10-31
- Last updated
- 2021-09-14
- Results posted
- 2021-09-14
Locations
36 sites across 9 countries: Bulgaria, Croatia, Finland, France, Oman, Romania, Slovakia, Sweden, Ukraine
Source: ClinicalTrials.gov record NCT03725852. Inclusion in this directory is not an endorsement.